What is MBX Biosciences, Inc.'s market cap?

MBX Biosciences, Inc. (MBX) has a market capitalization of $2.3B and trades on XNAS.

Who are MBX Biosciences, Inc.'s competitors?

MBX Biosciences, Inc.'s key competitors include Amylyx Pharmaceuticals, Viking Therapeutics, BridgeBio Pharma, and others. These companies compete in similar markets and product categories.

Who does MBX Biosciences, Inc. partner with?

MBX Biosciences, Inc.'s notable partners include Indiana University Research and Technology Corporation, Boehringer Ingelheim.

Where is MBX Biosciences, Inc. headquartered?

MBX Biosciences, Inc. is headquartered in United States of America and employs approximately 38 people. It has been publicly traded since 2024.

MBX Biosciences, Inc.

MBX

MBX Biosciences is a clinical-stage biopharmaceutical company focused on developing novel precision peptide therapies for endocrine and metabolic disorders.

Market cap

$2.3B+608%

Net income-$86.6M-17.9%

Free cash flow-$79.8M-18.6%

EPS (diluted)-$2.16+91.8%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

EPS-$0.51Beat by $0.11

Read the full report

Next report

Aug 6, 2026 (in a month)

EPS estimate-$0.68

Financials

Q1 2026

Income statement

See full

Operating income-$27.3M-2.8%

Net income-$23.5M+1.5%

EPS (diluted)-$0.50+29.6%

Balance sheet

See full

Cash & equivalents$45.2M+51.2%

Total debt$555.0K+327%

Total equity$437.8M+85.9%

Total assets$452.7M+84.1%

Cash flow

See full

Operating cash flow-$20.2M+10.9%

CapEx$437.0K+1,357%

Free cash flow-$20.6M+9.1%

Valuation & ratios

Valuation

See full

Market cap$2.21B+475%

Enterprise value$2.16B+533%

Returns & leverage

See full

Return on equity-25.7%—

Debt / equity0×0.0×

Current ratio30.8×+7.5×

Competitors

By market cap

Eli Lilly$987.23B

Amgen$187.28B

BridgeBio Pharma$13.4B

Viking Therapeutics$4.0B

Crinetics Pharmaceuticals$3.8B

MBX Biosciences, Inc.$2.2B

Nurix Therapeutics, Inc.$2.0B

Amylyx Pharmaceuticals, Inc.$1.8B

By revenue growth

Eli Lilly+47.4%

Nurix Therapeutics, Inc.+27.2%

Amgen+9.1%

Amylyx Pharmaceuticals, Inc.-100%

By net margin

Eli Lilly34.99%

Amgen20.96%

BridgeBio Pharma-125.85%

Nurix Therapeutics, Inc.-411.37%

Crinetics Pharmaceuticals-2,747.18%

Amylyx Pharmaceuticals, Inc.-45,096.15%

Profile

MBX Biosciences is a clinical-stage biopharmaceutical company focused on developing novel precision peptide therapies for endocrine and metabolic disorders. The company utilizes its proprietary Precision Endocrine Peptide (PEP) platform to engineer candidates with optimized pharmaceutical properties, such as extended half-lives and consistent drug concentrations, to improve clinical outcomes and simplify disease management.

Competitive position

Clinical-stage innovator leveraging a proprietary PEP platform to develop first-in-class or best-in-class once-weekly and once-monthly peptide therapies.

GeographiesUnited States, Europe

Customer segmentsEndocrine patients, Metabolic disorder patients

Business modelR&D intensive, IP licensing

SuppliersContract manufacturing organizations, Academic research institutions, Raw material suppliers for peptide synthesis

CustomersSpecialty pharmacies, Hospitals, Endocrinologists

CountryUnited States of America

Listed2024

Employees38.0

CEOPeter Kent Hawryluk

SectorPHARMACEUTICAL PREPARATIONS

IndustryPHARMACEUTICAL PREPARATIONS

Websitembxbio.com

FilingsSEC EDGAR

Questions, answered.

What is MBX Biosciences, Inc.'s market cap?: MBX Biosciences, Inc. (MBX) has a market capitalization of $2.3B and trades on XNAS.
Who are MBX Biosciences, Inc.'s competitors?: MBX Biosciences, Inc.'s key competitors include Amylyx Pharmaceuticals, Viking Therapeutics, BridgeBio Pharma, and others. These companies compete in similar markets and product categories.
Who does MBX Biosciences, Inc. partner with?: MBX Biosciences, Inc.'s notable partners include Indiana University Research and Technology Corporation, Boehringer Ingelheim.
Where is MBX Biosciences, Inc. headquartered?: MBX Biosciences, Inc. is headquartered in United States of America and employs approximately 38 people. It has been publicly traded since 2024.